Endologix to Present at the Canaccord Genuity 33rd Annual Growth Conference

IRVINE, Calif., Aug. 1, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that Shelley Thunen, Chief Financial Officer, is scheduled to present at the Canaccord Genuity 33rd Annual Growth Conference in Boston, MA.

Event: Canaccord Genuity 33rd Annual Growth Conference
Date: Thursday, August 15, 2013
Time: 6:30 a.m. PT / 9:30 a.m. ET

An audio webcast of the Company's presentation will be available by visiting the investor relations section of Endologix's website at www.endologix.com. A replay of the presentation will be available for 30 days.

About Endologix, Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. Endologix focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's website at www.endologix.com.

CONTACT: COMPANY CONTACT:

Endologix, Inc.
John McDermott, CEO
Shelley Thunen, CFO
(949) 595-7200
www.endologix.com

INVESTOR CONTACTS:
The Ruth Group
Nick Laudico
(646) 536-7030
Zack Kubow
(646) 536-7020

Source: Endologix

News Provided by Acquire Media